ARTICLE | Clinical News
FR104: Phase I started
July 20, 2015 7:00 AM UTC
Effimune began a double-blind, placebo-controlled, Belgian Phase I trial to evaluate single and multiple ascending doses of IV FR104 in 70 healthy volunteers. The Janssen Biotech Inc. subsidiary of J...